Pacific Edge in holding mode as US Medicare decision nears

Pacific Edge in holding mode as US Medicare decision nears
Total laboratory use of Pacific Edge's Cxbladder tests in the US rose in the 2024 financial year but the growth rate slowed in the second half as the company reduced its sales team. (Image: Thinkstock)
Greg Hurrell
Pacific Edge says the 2024 finance year has been one of two halves, as it quickly switched from growth to capital preservation.That sudden change of focus came from a major setback with the possible loss of access to the US Medicare system which has been its largest customer.The company reported a loss of $29.5 million for the March 31 financial year, 9.5% bigger than 2023’s net loss, amid that slowing growth.MedicareThe company said it was prepared for all outcomes as it waited to see whether it would hang on to its Medicare deal, which...

More Markets

THL's customer and revenue officer resigns
Markets

THL's customer and revenue officer resigns

New Zealand Exchnage-listed Tourism Holdings announced the resignation of its chief customer and revenue officer, Scott Fahey, on Tuesday morning.Tourism Holdings (THL) said Fahey's departure was because of a personal situation and it agreed to waive his notice period.Fahey h...

Seeka lifts earnings guidance again
Primary Sector

Seeka lifts earnings guidance again

Seeka has once again lifted its market guidance off the back of a “strong close out” to its 2024 year.The New Zealand Exchange-listed (NZX) horticulture business now expects full-year earnings at a profit before tax level for the year ended Dec 31 to be between $27.5 million and...

Fonterra's ingredients chief on second Trump presidency
Primary Sector

Fonterra's ingredients chief on second Trump presidency

The incoming US President has threatened tariffs on all imports.